SCHEMBL14523309

SCHEMBL14523309

CCCCCCCCCCCCCCCCCCOC[C@@H](O)COP(=O)(O)OCC[N+](C)(C)C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPAR5 Q9H1C0 1/20 0.66
▸ P2RY10 O00398 1/20 0.57
▸ PRKD3 O94806 2/20 0.55
▸ PRKCG P05129 2/20 0.55
▸ PRKCB P05771 2/20 0.55
▸ PRKCA P17252 2/20 0.55
▸ PRKCH P24723 2/20 0.55
▸ PRKCI P41743 2/20 0.55
▸ PRKCE Q02156 2/20 0.55
▸ PRKCQ Q04759 2/20 0.55
▸ PRKCZ Q05513 2/20 0.55
▸ PRKCD Q05655 2/20 0.55
▸ PRKD1 Q15139 2/20 0.55
▸ AKT1 P31749 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ GMNN O75496 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28666820 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL28668717 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL28688761 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL14363934 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL11889677 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL7592844 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL20851998 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL20852013 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL20851912 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB
SCHEMBL28679209 1.00 LPAR5 (0.66) LPAR5P2RY10PRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090561-A1 LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS AKER BIOMARINE HUMAN INGREDIENTS AS (NO) 2025-03-20 — — US claimed
WO-2022255782-A1 BIOMARKERS FOR PREDICTING RESPONSE TO TREATMENT OF RHEUMATOID ARTHRITIS 가톨릭대학교 산학협력단 2022-12-08 — — WO claimed
WO-2022255781-A1 BIOMARKER FOR DISEASE ACTIVITY ASSESSMENT, DIAGNOSIS, AND ONSET PREDICTION OF RHEUMATOID ARTHRITIS 가톨릭대학교 산학협력단 2022-12-08 — — WO claimed
EP-3727037-B1 LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS AKER BIOMARINE HUMAN INGREDIENTS AS (NO) 2025-10-08 — — EP disclosed
US-20250090561-A1 LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS AKER BIOMARINE HUMAN INGREDIENTS AS (NO) 2025-03-20 — — US disclosed
US-20240424791-A1 PROCESS FOR AN IPC COATING FUJIFILM DIMATIX INC (US) 2024-12-26 — — US disclosed
US-20240424788-A1 IPC COATING FOR PRINTHEAD FUJIFILM DIMATIX INC (US) 2024-12-26 — — US disclosed
WO-2024243201-A2 A METHOD OF PROVIDING EARLY INTERVENTION TO A NEWBORN OR INFANT WITH AUTISM SPECTRUM DISORDER THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-11-28 — — WO disclosed
US-12076333-B2 Lysophosphatidylcholine compositions AKER BIOMARINE HUMAN INGREDIENTS AS (NO) 2024-09-03 — — US disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 — — US disclosed
WO-2022255782-A1 BIOMARKERS FOR PREDICTING RESPONSE TO TREATMENT OF RHEUMATOID ARTHRITIS 가톨릭대학교 산학협력단 2022-12-08 — — WO disclosed
WO-2022255781-A1 BIOMARKER FOR DISEASE ACTIVITY ASSESSMENT, DIAGNOSIS, AND ONSET PREDICTION OF RHEUMATOID ARTHRITIS 가톨릭대학교 산학협력단 2022-12-08 — — WO disclosed
CN-110022859-A Liposomes with unique MR characteristics19Hydrophilic fluorinated molecules for F MRI probes 德克萨斯州儿童医院 2019-07-16 — — CN disclosed
CN-109477071-A The 3D printing of cellularised bracket 牛津大学创新有限公司 2019-03-15 — — CN disclosed
CN-107920964-A Fusogenic liposome-coated porous silicon nanoparticles 加利福尼亚大学董事会 2018-04-17 — — CN disclosed
US-20070077283-A1 METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS NASTECH PHARMACEUTICAL COMPANY INC. 2007-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070077283-A1 METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS PGF, PLAT, PTAFR LPAR5 68/4885P2RY10 407/4885PRKD3 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback